Atypical artificial cells: Novel biomimetic materials for combating cancer

Abstract

The functional concept of using synthetic entities to supplement or replace certain functions or structures of biological cells is realized by the development of atypical artificial cells using a bottom-up approach. Tremendous progress has been achieved over the past 5 years that focuses on the therapeutic applications of atypical artificial cells, especially in the anticancer arena. Artificial cell-based anticancer strategies have demonstrated eminent advantages over conventional anticancer tactics, with excellent biocompatibility and targeting capability. The present review commences with introducing the constructing principles and classification of artificial cells. Artificial cell-based applications in cancer prophylaxis, diagnosis, and treatment are subsequently highlighted. These stimulating outcomes may inspire the development of next-generation anticancer therapeutic strategies.

Keywords

atypical artificial cells / bottom-up assembly / cancer diagnosis / cancer therapeutics / nanomedicine

References

[1] Hyllner J, Mason C, Wilmut I. Cells: from Robert Hooke to cell therapy—a 350 year journey. Philos Trans R Soc B. 2015;370(1680):20150320.

[2] Stuart T, Butler A, Hoffman P, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888–1902.

[3] Cho E, Lu Y. Compartmentalizing cell-free systems: toward creating life-like artificial cells and beyond. ACS Synth Biol. 2020;9(11):2881–2901.

[4] Chang TMS. Artificial cell evolves into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, replicating synthetic cells, cell encapsulation/scaffold, biosorbent/immunosorbent haemoperfusion/plasmapheresis, regenerative medicine, encapsulated microbe, nanobiotechnology, nanotechnology. Artif Cells Nanomed Biotechnol. 2019;47(1):997–1013.

[5] Li J, Baxani DK, Jamieson WD, et al. Formation of polarized, functional artificial cells from compartmentalized droplet networks and nanomaterials, using one-step, dual-material 3D-printed microfluidics. Adv Sci. 2020;7(1):1901719.

[6] McGuire S. World cancer report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 2016;7(2):418–419.

[7] Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505–527.

[8] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.

[9] Zhang Y, Wang F, Shi L, et al. Nanoscale coordination polymers enabling antioxidants inhibition for enhanced chemodynamic therapy. J Controlled Release. 2023;354:196–206.

[10] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

[11] Pearce A, Haas M, Viney R, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: a prospective cohort study. PLoS ONE. 2017;12(10):e0184360.

[12] Sardain H, Lavoue V, Redpath M, Bertheuil N, Foucher F, Levêque J. Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic review. EJSO. 2015;41(8):975–985.

[13] Nougaret S, Vargas HA, Lakhman Y, et al. Intravoxel incoherent motion-derived histogram metrics for assessment of response after combined chemotherapy and radiation therapy in rectal cancer: initial experience and comparison between single-section and volumetric analyses. Radiology. 2016;280(2):446–454.

[14] Tao JJ, Visvanathan K, Wolff AC. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast. 2015;24(2): S149–S153.

[15] Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193–199.

[16] Elani Y. Interfacing living and synthetic cells as an emerging frontier in synthetic biology. Angew Chem Int Ed. 2021;60(11):5602–5611.

[17] Damiano L, Stano P. On the “Life-Likeness” of synthetic cells. Front Bioeng Biotechnol. 2020;8:953.

[18] Salehi-Reyhani A, Ces O, Elani Y. Artificial cell mimics as simplified models for the study of cell biology. Exp Biol Med. 2017;242(13):1309–1317.

[19] Buddingh’ BC, van Hest JCM. Artificial cells: synthetic compartments with life-like functionality and adaptivity. Acc Chem Res. 2017;50(4):769–777.

[20] Yewdall NA, Mason AF, van Hest JCM. The hallmarks of living systems: towards creating artificial cells. Interface Focus. 2018;8(5):20180023.

[21] Xu C, Hu S, Chen X. Artificial cells: from basic science to applications. Mater Today. 2016;19(9):516–532.

[22] Osaki T, Takeuchi S. Artificial cell membrane systems for biosensing applications. Anal Chem. 2017;89(1):216–231.

[23] Li S, Wang X, Mu W, Han X. Chemical signal communication between two protoorganelles in a lipid-based artificial cell. Anal Chem. 2019;91(10):6859–6864.

[24] Hennig S, Rödel G, Ostermann K. Artificial cell–cell communication as an emerging tool in synthetic biology applications. J Biol Eng. 2015;9:13.

[25] York-Duran MJ, Godoy-Gallardo M, Labay C, Urquhart AJ, Andresen TL, Hosta-Rigau L. Recent advances in compartmentalized synthetic architectures as drug carriers, cell mimics and artificial organelles. Colloids Surf B. 2017;152:199–213.

[26] Gao M, Liang C, Song X, et al. Erythrocyte-membrane-enveloped perfluorocarbon as nanoscale artificial red blood cells to relieve tumor hypoxia and enhance cancer radiotherapy. Adv Mater. 2017;29(35):1701429.

[27] Deng NN, Yelleswarapu M, Zheng L, Huck WTS. Microfluidic assembly of monodisperse vesosomes as artificial cell models. J Am Chem Soc. 2017;139(2):587–590.

[28] Sato Y, Takinoue M. Creation of artificial cell-like structures promoted by microfluidics technologies. Micromachines. 2019;10(4):216.

[29] Byeon HJ, Thao LQ, Lee S, et al. Doxorubicin-loaded nanoparticles consisted of cationic-and mannose-modified-albumins for dual-targeting in brain tumors. J Controll Release. 2016;225:301–313.

[30] Duan L, Yan X, Wang A, Jia Y, Li J. Highly loaded hemoglobin spheres as promising artificial oxygen carriers. ACS Nano. 2012;6(8):6897–6904.

[31] Su J, Sun H, Meng Q, Zhang P, Yin Q, Li Y. Enhanced blood suspensibility and laser-activated tumor-specific drug release of theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes. Theranostics. 2017;7(3):523–537.

[32] Wang Y, Zhang K, Qin X, et al. Biomimetic nanotherapies: red blood cell based core-shell structured nanocomplexes for atherosclerosis management. Adv Sci. 2019;6(12):1900172.

[33] Ajdari N, Vyas C, Bogan SL, Lwaleed BA, Cousins BG. Gold nanoparticle interactions in human blood: a model evaluation. Nanomed Nanotechnol Biol Med. 2017;13(4):1531–1542.

[34] Lazarovits J, Chen YY, Sykes EA, Chan WCW. Nanoparticle-blood interactions: the implications on solid tumour targeting. Chem Commun. 2015;51(14):2756–2767.

[35] Fan W, Yung B, Huang P, Chen X. Nanotechnology for multimodal synergistic cancer therapy. Chem Rev. 2017;117(22):13566–13638.

[36] Wei X, Gao J, Fang RH, et al. Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia. Biomaterials. 2016;111:116–123.

[37] Sun H, Su J, Meng Q, et al. Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors. Adv Mater. 2016;28(43):9581–9588.

[38] Yi T, Li J, Chen H, et al. Splenic dendritic cells survey red blood cells for missing self-CD47 to trigger adaptive immune responses. Immunity. 2015;43(4):764–775.

[39] Kroll AV, Fang RH, Zhang L. Biointerfacing and applications of cell membrane-coated nanoparticles. Bioconjug Chem. 2017;28(1):23–32.

[40] Thakor AS, Gambhir SS. Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J Clin. 2013;63(6):395–418.

[41] Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharmaceut Biopharmaceut. 2008;69(1):1–9.

[42] Ta HT, Truong NP, Whittaker AK, Davis TP, Peter K. The effects of particle size, shape, density and flow characteristics on particle margination to vascular walls in cardiovascular diseases. Expert Opin Drug Delivery. 2018;15(1):33–45.

[43] Xie W, Deng WW, Zan M, et al. Cancer cell membrane camouflaged nanoparticles to realize starvation therapy together with checkpoint blockades for enhancing cancer therapy. ACS Nano. 2019;13(3):2849–2857.

[44] Lu Y, Hu Q, Jiang C, Gu Z. Platelet for drug delivery. Curr Opin Biotechnol. 2019;58:81–91.

[45] Luk BT, Zhang L. Cell membrane-camouflaged nanoparticles for drug delivery. J Controlled Release. 2015;220(Pt B):600–607.

[46] Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials. 2016;85:152–167.

[47] Ulbrich K, Holá K, Šubr V, Bakandritsos A, Tuček J, Zbořil R. Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. Chem Rev. 2016;116(9):5338–5431.

[48] Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17–38.

[49] Chen G, Roy I, Yang C, Prasad PN. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem Rev. 2016;116(5):2826–2885.

[50] Ngoune R, Peters A, von Elverfeldt D, Winkler K, Pütz G. Accumulating nanoparticles by EPR: a route of no return. J Controll Release. 2016;238:58–70.

[51] Tanaka N, Kanatani S, Tomer R, et al. Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity. Nat Biomed Eng. 2017;1(10):796–806.

[52] Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3–6.

[53] Li R, Xie Y. Nanodrug delivery systems for targeting the endogenous tumor microenvironment and simultaneously overcoming multidrug resistance properties. J Controll Release. 2017;251:49–67.

[54] Dai L, Liu J, Luo Z, Li M, Cai K. Tumor therapy: targeted drug delivery systems. J Mater Chem B. 2016;4(42):6758–6772.

[55] Srinivasarao M, Low PS. Ligand-targeted drug delivery. Chem Rev. 2017;117(19):12133–12164.

[56] Ding H, Lv Y, Ni D, et al. Erythrocyte membrane-coated NIR-triggered biomimetic nanovectors with programmed delivery for photodynamic therapy of cancer. Nanoscale. 2015;7(21):9806–9815.

[57] Chai Z, Hu X, Wei X, et al. A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery. J Controll Release. 2017;264:102–111.

[58] Xu L, Su T, Xu X, Zhu L, Shi L. Platelets membrane camouflaged irinotecan-loaded gelatin nanogels for in vivo colorectal carcinoma therapy. J Drug Delivery Sci Technol. 2019;53:101190.

[59] Viens LJ, Henley SJ, Watson M, et al. Human papillomavirus-associated cancers—United States, 2008–2012. MMWR Morb Mortal Wkly Rep. 2016;65(26):661–666.

[60] Zhu DM, Xie W, Xiao YS, et al. Erythrocyte membrane-coated gold nanocages for targeted photothermal and chemical cancer therapy. Nanotechnology. 2018;29(8):084002.

[61] Romero P, Banchereau J, Bhardwaj N, et al. The human vaccines project: a roadmap for cancer vaccine development. Sci Transl Med. 2016;8(334):334–339.

[62] Smyth MJ, Ngiow SF, Ribas A, Teng MWL. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13(3):143–158.

[63] Chen Q, Bai H, Wu W, et al. Bioengineering bacterial vesicle-coated polymeric nanomedicine for enhanced cancer immunotherapy and metastasis prevention. Nano Lett. 2020;20(1):11–21.

[64] Wang S, Gao J, Wang Z. Outer membrane vesicles for vaccination and targeted drug delivery. WIREs Nanomed Nanobiotechnol. 2019;11(2):e1523.

[65] Gujrati V, Kim S, Kim SH, et al. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano. 2014;8(2):1525–1537.

[66] Shi J, Ma Z, Pan H, et al. Biofilm-encapsulated nano drug delivery system for the treatment of colon cancer. J Microencapsul. 2020;37(7):481–491.

[67] Gujrati V, Prakash J, Malekzadeh-Najafabadi J, et al. Bioengineered bacterial vesicles as biological nano-heaters for optoacoustic imaging. Nat Commun. 2019;10(1):1114.

[68] Gao J, Wang S, Dong X, Wang Z. RGD-expressed bacterial membrane-derived nanovesicles enhance cancer therapy via multiple tumorous targeting. Theranostics. 2021;11(7):3301–3316.

[69] Shimodaira S, Sano K, Hirabayashi K, et al. Dendritic cell-based adjuvant vaccination targeting wilms’tumor 1 in patients with advanced colorectal cancer. Vaccines. 2015;3(4):1004–1018.

[70] Melief CJM, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125(9):3401–3412.

[71] Fan Y, Moon J. Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccines. 2015;3(3):662–685.

[72] Hellmann MD, Friedman CF, Wolchok JD. Combinatorial cancer immunotherapies. Adv Immunol. 2016;130:251–277.

[73] Thomas A, Giaccone G. Why has active immunotherapy not worked in lung cancer? Ann Oncol. 2015;26(11):2213–2220.

[74] Jahromi LP, Fuhrmann G. Bacterial extracellular vesicles: understanding biology promotes applications as nanopharmaceuticals. Adv Drug Deliv Rev. 2021;173:125–140.

[75] Zhu Z, Antenucci F, Villumsen KR, Bojesen AM. Bacterial outer membrane vesicles as a versatile tool in vaccine research and the fight against antimicrobial resistance. mBio. 2021;12(4):e0170721.

[76] Sartorio MG, Pardue EJ, Feldman MF, Haurat MF. Bacterial outer membrane vesicles: from discovery to applications. Annu Rev Microbiol. 2021;75:609–630.

[77] Turner L, Bitto NJ, Steer DL, et al. Helicobacter pylori outer membrane vesicle size determines their mechanisms of host cell entry and protein content. Front Immunol. 2018;9:1466.

[78] Gnopo YMD, Watkins HC, Stevenson TC, DeLisa MP, Putnam D. Designer outer membrane vesicles as immunomodulatory systems—reprogramming bacteria for vaccine delivery. Adv Drug Deliv Rev. 2017;114:132–142.

[79] Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16(7):748–759.

[80] Peng LH, Wang MZ, Chu Y, et al. Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL-programmed therapy against melanoma. Sci Adv. 2020;6(27):eaba2735.

[81] Cheng K, Zhao R, Li Y, et al. Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology. Nat Commun. 2021;12(1):2041.

[82] Rappazzo CG, Watkins HC, Guarino CM, et al. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice. Vaccine. 2016;34(10):1252–1258.

[83] Brune KD, Leneghan DB, Brian IJ, et al. Plug-and-display: decoration of virus-like particles via isopeptide bonds for modular immunization. Sci Rep. 2016;6:19234.

[84] Ye T, Li F, Ma G, Wei W. Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors. Adv Drug Deliv Rev. 2021;177:113927.

[85] Chen Q, Huang G, Wu W, et al. A hybrid eukaryotic-prokaryotic nanoplatform with photothermal modality for enhanced antitumor vaccination. Adv Mater. 2020;32(16):e1908185.

[86] Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255.

[87] Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.

[88] Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–742.

[89] Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019;19(10):568–586.

[90] Lian S, Xie R, Ye Y, et al. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells. Sci Rep. 2019;9(1):4532.

[91] Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRPαsignaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276(1):145–164.

[92] Candas-Green D, Xie B, Huang J, et al. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat Commun. 2020;11(1):4591.

[93] Hayat SMG, Bianconi V, Pirro M, Jaafari MR, Hatamipour M, Sahebkar A. CD47: role in the immune system and application to cancer therapy. Cell Oncol. 2020;43(1):19–30.

[94] Choo YW, Kang M, Kim HY, et al. M1 macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors. ACS Nano. 2018;12(9):8977–8993.

[95] Wang P, Wang H, Huang Q, et al. Exosomes from M1-polarized macrophages enhance paclitaxel antitumor activity by activating macrophages-mediated inflammation. Theranostics. 2019;9(6):1714–1727.

[96] Rao L, Wu L, Liu Z, et al. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis. Nat Commun. 2020;11(1):4909.

[97] Swart M, Verbrugge I, Beltman JB. Combination approaches with immune-checkpoint blockade in cancer therapy. Front Oncol. 2016;6:233.

[98] Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers. 2020;12(3):738.

[99] Zeng T, Qin Q, Bian Z, Li J. Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC). Artif Cells Nanomed Biotechnol. 2019;47(1):4194–4201.

[100] Liu C, Seeram NP, Ma H. Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review. Cancer Cell Int. 2021;21(1):239.

[101] Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12(1):92.

[102] Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330.

[103] Zhang J, Yan Y, Li J, Adhikari R, Fu L. PD-1/PD-L1 based combinational cancer therapy: icing on the cake. Front Pharmacol. 2020;11:722.

[104] Bryan CM, Rocklin GJ, Bick MJ, et al. Computational design of a synthetic PD-1 agonist. Proc Natl Acad Sci. 2021;118(29):e2102164118.

[105] Qiao Y, Qiu Y, Ding J, et al. Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity. Nat Commun. 2021;12(1):6360.

[106] Fan Q, Chen Z, Wang C, Liu Z. Toward biomaterials for enhancing immune checkpoint blockade therapy. Adv Funct Mater. 2018;28(37):1802540.

[107] Kosmides AK, Meyer RA, Hickey JW, et al. Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma. Biomaterials. 2017;118:16–26.

[108] Jo SD, Nam G-H, Kwak G, Yang Y, Kwon IC. Harnessing designed nanoparticles: current strategies and future perspectives in cancer immunotherapy. Nano Today. 2017;17:23–37.

[109] Masoumi E, Tahaghoghi-Hajghorbani S, Jafarzadeh L, Sanaei MJ, Pourbagheri-Sigaroodi A, Bashash D. The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle. J Controll Release. 2021;340:168–187.

[110] Chugh V, Vijaya Krishna K, Pandit A. Cell membrane-coated mimics: a methodological approach for fabrication, characterization for therapeutic applications, and challenges for clinical translation. ACS Nano. 2021;15(11):17080–17123.

[111] Lu Q, Ye H, Wang K, et al. Bioengineered platelets combining chemotherapy and immunotherapy for postsurgical melanoma treatment: internal core-loaded doxorubicin and external surface-anchored anti-PD-L1 antibody backpacks. Nano Lett. 2022;22(7):3141–3150.

[112] Fabricius HÅ, Starzonek S, Lange T. The role of platelet cell surface P-selectin for the direct platelet-tumor cell contact during metastasis formation in human tumors. Front Oncol. 2021;11:642761.

[113] Stoiber D, Assinger A. Platelet-leukocyte interplay in cancer development and progression. Cells. 2020;9(4):855.

[114] Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9):170070.

[115] Jiang R, Agrawal S, Aghaamoo M, Parajuli R, Agrawal A, Lee AP. Rapid isolation of circulating cancer associated fibroblasts by acoustic microstreaming for assessing metastatic propensity of breast cancer patients. Lab Chip. 2021;21(5):875–887.

[116] Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discovery. 2016;6(5):479–491.

[117] Schuster E, Taftaf R, Reduzzi C, Albert MK, Romero-Calvo I, Liu H. Better together: circulating tumor cell clustering in metastatic cancer. Trends Cancer. 2021;7(11):1020–1032.

[118] Zhang W, Wang G, Liu Y, et al. The synergistic effect of hierarchical micro/nano-topography and bioactive ions for enhanced osseointegration. Biomaterials. 2013;34(13):3184–3195.

[119] Zhang W, Li Z, Huang Q, et al. Effects of a hybrid micro/nanorod topography-modified titanium implant on adhesion and osteogenic differentiation in rat bone marrow mesenchymal stem cells. Int J Nanomed. 2013;8:257–265.

[120] Lou YR, Kanninen L, Kaehr B, et al. Silica bioreplication preserves three-dimensional spheroid structures of human pluripotent stem cells and HepG2 cells. Sci Rep. 2015;5:13635.

[121] Kaehr B, Townson JL, Kalinich RM, et al. Cellular complexity captured in durable silica biocomposites. Proc Natl Acad Sci. 2012;109(43):17336–17341.

[122] Huang C, Yang G, Ha Q, Meng J, Wang S. Multifunctional “smart” particles engineered from live immunocytes: toward capture and release of cancer cells. Adv Mater. 2015;27(2):310–313.

[123] Ding P, Wang Z, Wu Z, Zhou Y, Sun N, Pei R. Natural biointerface based on cancer cell membranes for specific capture and release of circulating tumor cells. ACS Appl Mater Interfaces. 2020;12(18):20263–20270.

[124] Gkountela S, Castro-Giner F, Szczerba BM, et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell. 2019;176(1-2):98–112.e14.

[125] Satelli A, Brownlee Z, Mitra A, Meng QH, Li S. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule-and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem. 2015;61(1):259–266.

[126] Goodman CR, Seagle BLL, Friedl TWP, et al. Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer. JAMA Oncol. 2018;4(8):e180163.

[127] Ou H, Huang Y, Xiang L, et al. Circulating tumor cell phenotype indicates poor survival and recurrence after surgery for hepatocellular carcinoma. Dig Dis Sci. 2018;63(9):2373–2380.

[128] Zhang D, Zhao L, Zhou P, et al. Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy. Cancer Cell Int. 2017;17:6.

[129] Zhang Z, Xiao Y, Zhao J, et al. Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer. Respirology. 2016;21(3):519–525.

[130] Xie C, Zhen X, Miao Q, Lyu Y, Pu K. Self-assembled semiconducting polymer nanoparticles for ultrasensitive near-infrared afterglow imaging of metastatic tumors. Adv Mater. 2018;30(21):e1801331.

[131] Brito AE, Santos A, Sasse AD, et al. 18F-fluoride PET/CT tumor burden quantification predicts survival in breast cancer. Oncotarget. 2017;8(22):36001–36011.

[132] Wen S, Zhou J, Zheng K, Bednarkiewicz A, Liu X, Jin D. Advances in highly doped upconversion nanoparticles. Nat Commun. 2018;9(1):2415.

[133] Idris NM, Jayakumar MKG, Bansal A, Zhang Y. Upconversion nanoparticles as versatile light nanotransducers for photoactivation applications. Chem Soc Rev. 2015;44(6):1449–1478.

[134] Grzyb T, Mrówczyńska L, Szczeszak A, et al. Synthesis, characterization, and cytotoxicity in human erythrocytes of multifunctional, magnetic, and luminescent nanocrystalline rare earth fluorides. J Nanoparticle Res. 2015;17(10):399.

[135] Wang X, Valiev RR, Ohulchanskyy TY, Ågren H, Yang C, Chen G. Dye-sensitized lanthanide-doped upconversion nanoparticles. Chem Soc Rev. 2017;46(14):4150–4167.

[136] Rao L, Bu LL, Cai B, et al. Cancer cell membrane-coated upconversion nanoprobes for highly specific tumor imaging. Adv Mater. 2016;28(18):3460–3466.

[137] Fang H, Li M, Liu Q, et al. Ultra-sensitive nanoprobe modified with tumor cell membrane for UCL/MRI/PET multimodality precise imaging of triple-negative breast cancer. Nano Micro Lett. 2020;12(1):62.

[138] Zhang X, He S, Ding B, et al. Cancer cell membrane-coated rare earth doped nanoparticles for tumor surgery navigation in NIR-II imaging window. Chem Eng J. 2020;385:123959.

[139] Nakamura Y, Mochida A, Choyke PL, Kobayashi H. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug Chem. 2016;27(10):2225–2238.

[140] Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373–2387.

[141] Kai MP, Brighton HE, Fromen CA, et al. Tumor presence induces global immune changes and enhances nanoparticle clearance. ACS Nano. 2016;10(1):861–870.

[142] Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014.

[143] Dehaini D, Wei X, Fang RH, et al. Erythrocyte–platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv Mater. 2017;29(16):1606209.

[144] Fam SY, Chee CF, Yong CY, Ho KL, Mariatulqabtiah AR, Tan WS. Stealth coating of nanoparticles in drug-delivery systems. Nanomaterials. 2020;10(4):787.

[145] Zhai Y, Su J, Ran W, et al. Preparation and application of cell membrane-camouflaged nanoparticles for cancer therapy. Theranostics. 2017;7(10):2575–2592.

[146] Hu CMJ, Fang RH, Wang KC, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015;526(7571):118–121.

[147] Narain A, Asawa S, Chhabria V, Patil-Sen Y. Cell membrane coated nanoparticles: next-generation therapeutics. Nanomedicine. 2017;12(21):2677–2692.

[148] Lv Z, Bian Z, Shi L, et al. Loss of cell surface CD47 clustering formation and binding avidity to SIRPα facilitate apoptotic cell clearance by macrophages. J Immunol. 2015;195(2):661–671.

[149] Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. WIREs Nanomed Nanobiotechnol. 2015;7(5):655–677.

[150] Villa CH, Anselmo AC, Mitragotri S, Muzykantov V. Red blood cells: supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems. Adv Drug Deliv Rev. 2016;106(Pt A):88–103.

[151] Jiang Q, Luo Z, Men Y, et al. Red blood cell membrane-camouflaged melanin nanoparticles for enhanced photothermal therapy. Biomaterials. 2017;143:29–45.

[152] Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting strategies for tissue-specific drug delivery. Cell. 2020;181(1):151–167.

[153] Glassman PM, Villa CH, Ukidve A, et al. Vascular drug delivery using carrier red blood cells: focus on RBC surface loading and pharmacokinetics. Pharmaceutics. 2020;12(5):440.

[154] Sahoo K, Karumuri S, Hikkaduwa Koralege RS, et al. Molecular and biocompatibility characterization of red blood cell membrane targeted and cell-penetrating-peptide-modified polymeric nanoparticles. Mol Pharm. 2017;14(7):2224–2235.

[155] Gremmel T, Frelinger, 3rd A, Michelson A. Platelet physiology. Semin Thromb Hemost. 2016;42(3):191–204.

[156] Paniccia R, Priora R, Alessandrello Liotta A, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag. 2015;11:133–148.

[157] Zhang C, Ni D, Liu Y, Yao H, Bu W, Shi J. Magnesium silicide nanoparticles as a deoxygenation agent for cancer starvation therapy. Nat Nanotechnol. 2017;12(4):378–386.

[158] Hu Q, Sun W, Qian C, Wang C, Bomba HN, Gu Z. Anticancer platelet-mimicking nanovehicles. Adv Mater. 2015;27(44):7043–7050.

[159] Contursi A, Sacco A, Grande R, Dovizio M, Patrignani P. Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting. Cell Mol Life Sci. 2017;74(19):3491–3507.

[160] Lavergne M, Janus-Bell E, Schaff M, Gachet C, Mangin P. Platelet integrins in tumor metastasis: do they represent a therapeutic target? Cancers. 2017;9(10):133.

[161] Tesfamariam B. Involvement of platelets in tumor cell metastasis. Pharmacol Ther. 2016;157:112–119.

[162] Tang S, Zhang F, Gong H, et al. Enzyme-powered Janus platelet cell robots for active and targeted drug delivery. Sci Rob. 2020;5(43):eaba6137.

[163] Xu L, Wu S, Wang J. Cancer cell membrane-coated nanocarriers for homologous target inhibiting the growth of hepatocellular carcinoma. J Bioact Compat Polym. 2018;34(1):58–71.

[164] Li H, Lu J, Yan C, Xu L. Tumor cell membrane-coated biomimetic nanoplatform for homologous targeted therapy of colorectal carcinoma. Int J Polym Mater Polym Biomater. 2020;69(18):1157–1166.

[165] Bose RJ, Paulmurugan R, Moon J, Lee SH, Park H. Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics. Drug Discovery Today. 2018;23(4):891–899.

[166] Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol. 2015;16(1):1.

[167] Zeng Z, Pu K. Improving cancer immunotherapy by cell membrane-camouflaged nanoparticles. Adv Funct Mater. 2020;30(43):04397.

[168] Xuan M, Shao J, Zhao J, Li Q, Dai L, Li J. Magnetic mesoporous silica nanoparticles cloaked by red blood cell membranes: applications in cancer therapy. Angew Chem Int Ed. 2018;57(21):6049–6053.

[169] Su J, Sun H, Meng Q, et al. Long circulation red-blood-cell-mimetic nanoparticles with peptide-enhanced tumor penetration for simultaneously inhibiting growth and lung metastasis of breast cancer. Adv. Funct. Mater. 2016;26(8):1243–1252.

[170] Wang X, Li H, Liu X, et al. Enhanced photothermal therapy of biomimetic polypyrrole nanoparticles through improving blood flow perfusion. Biomaterials. 2017;143:130–141.

[171] Aryal S, Hu CMJ, Fang RH, et al. Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug loading and release. Nanomedicine. 2013;8(8):1271–1280.

[172] Xing L, Shi Q, Zheng K, et al. Ultrasound-mediated microbubble destruction (UMMD) facilitates the delivery of CA19-9 targeted and paclitaxel loaded mPEG-PLGA-PLL nanoparticles in pancreatic cancer. Theranostics. 2016;6(10):1573–1587.

[173] Jiang Q, Wang K, Zhang X, et al. Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy. Small. 2020;16(22):e2001704.

[174] Su J, Sun H, Meng Q, Zhang P, Yin Q, Li Y. Enhanced blood suspensibility and laser-activated tumor-specific drug release of theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes: erratum. Theranostics. 2020;10(5):2401.

[175] Zhang B, Li H, Pan W, Chen Q, Ouyang Q, Zhao J. Dual-color upconversion nanoparticles (UCNPs)-based fluorescent immunoassay probes for sensitive sensing foodborne pathogens. Food Anal Methods. 2017;10(6):2036–2045.

[176] Piao JG, Wang L, Gao F, You YZ, Xiong Y, Yang L. Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. ACS Nano. 2014;8(10):10414–10425.

[177] Sahoo N, Sahoo RK, Biswas N, Guha A, Kuotsu K. Recent advancement of gelatin nanoparticles in drug and vaccine delivery. Int J Biol Macromol. 2015;81:317–331.

[178] Zhang Y, Wei J, Liu S, et al. Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics. 2017;7(5):1062–1071.

[179] Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.

[180] Zhang Y, Liu G, Wei J, Nie G. Platelet membrane-based and tumor-associated platelettargeted drug delivery systems for cancer therapy. Front Med. 2018;12(6):667–677.

[181] Stewart C, Konstantinov K, McKinnon S, et al. First proof of bismuth oxide nanoparticles as efficient radiosensitisers on highly radioresistant cancer cells. Phys Med. 2016;32(11):1444–1452.

[182] Liu Y, Wang X, Ouyang B, et al. Erythrocyte–platelet hybrid membranes coating polypyrrol nanoparticles for enhanced delivery and photothermal therapy. J Mater Chem B. 2018;6(43):7033–7041.

[183] Xuan M, Shao J, Dai L, He Q, Li J. Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in vivo cancer therapy. Adv Healthcare Mater. 2015;4(11):1645–1652.

[184] Zhang L, Wang Z, Zhang Y, et al. Erythrocyte membrane cloaked metal–organic framework nanoparticle as biomimetic nanoreactor for starvation-activated colon cancer therapy. ACS Nano. 2018;12(10):10201–10211.

[185] Lopes J, Lopes D, Pereira-Silva M, et al. Macrophage cell membrane-cloaked nanoplatforms for biomedical applications. Small Methods. 2022;6(8):e2200289.

[186] Sun H, Su J, Meng Q, et al. Cancer cell membrane-coated gold nanocages with hyperthermia-triggered drug release and homotypic target inhibit growth and metastasis of breast cancer. Adv Funct Mater. 2017;27(3):1604300.

[187] Cui F, Ji J, Sun J, et al. A novel magnetic fluorescent biosensor based on graphene quantum dots for rapid, efficient, and sensitive separation and detection of circulating tumor cells. Anal Bioanal Chem. 2019;411(5):985–995.

[188] Pan W, Cui B, Gao P, Ge Y, Li N, Tang B. A cancer cell membrane-camouflaged nanoreactor for enhanced radiotherapy against cancer metastasis. Chem Commun. 2020;56(4):547–550.

[189] Li S, Jiang W, Yuan Y, et al. Delicately designed cancer cell membrane-camouflaged nanoparticles for targeted (19)F MR/PA/FL imaging-guided photothermal therapy. ACS Appl Mater Interfaces. 2020;12(51):57290–57301.

[190] Zhou M, Xing Y, Li X, Du X, Xu T, Zhang X. Cancer cell membrane camouflaged semi-yolk@spiky-shell nanomotor for enhanced cell adhesion and synergistic therapy. Small. 2020;16(39):e2003834.

[191] Tian H, Luo Z, Liu L, et al. Cancer cell membrane-biomimetic oxygen nanocarrier for breaking hypoxia-induced chemoresistance. Adv Funct Mater. 2017;27(38):1703197.

[192] Chen Z, Zhao P, Luo Z, et al. Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano. 2016;10(11):10049–10057.

[193] Chen M, Chen M, He J. Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA. Artif Cells Nanomed Biotechnol. 2019;47(1):1635–1641.

[194] Zhao Z, Ji M, Wang Q, He N, Li Y. Ca²⁺ signaling modulation using cancer cell membrane coated chitosan nanoparticles to combat multidrug resistance of cancer. Carbohydr Polym. 2020;238:116073.

[195] Jin J, Krishnamachary B, Barnett JD, et al. Human cancer cell membrane-coated biomimetic nanoparticles reduce fibroblast-mediated invasion and metastasis and induce T-cells. ACS Appl Mater Interfaces. 2019;11(8):7850–7861.

[196] Pei Q, Hu X, Zheng X, et al. Light-activatable red blood cell membrane-camouflaged dimeric prodrug nanoparticles for synergistic photodynamic/chemotherapy. ACS Nano. 2018;12(2):1630–1641.

[197] Ren X, Zheng R, Fang X, et al. Red blood cell membrane camouflaged magnetic nanoclusters for imaging-guided photothermal therapy. Biomaterials. 2016;92:13–24.

[198] Chen W, Zeng K, Liu H, et al. Cell membrane camouflaged hollow Prussian blue nanoparticles for synergistic photothermal-/chemotherapy of cancer. Adv Funct Mater. 2017;27(11):1605795.

[199] Luk BT, Fang RH, Hu CMJ, et al. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics. 2016;6(7):1004–1011.

[200] Deng J, Xu S, Hu W, Xun X, Zheng L, Su M. Tumor targeted, stealthy and degradable bismuth nanoparticles for enhanced X-ray radiation therapy of breast cancer. Biomaterials. 2018;154:24–33.

[201] Rao L, Cai B, Bu LL, et al. Microfluidic electroporation-facilitated synthesis of erythrocyte membrane-coated magnetic nanoparticles for enhanced imaging-guided cancer therapy. ACS Nano. 2017;11(4):3496–3505.

[202] Li J, Zhen X, Lyu Y, Jiang Y, Huang J, Pu K. Cell membrane coated semiconducting polymer nanoparticles for enhanced multimodal cancer phototheranostics. ACS Nano. 2018;12(8):8520–8530.

[203] Ren H, Liu J, Li Y, et al. Oxygen self-enriched nanoparticles functionalized with erythrocyte membranes for long circulation and enhanced phototherapy. Acta Biomater. 2017;59:269–282.

[204] Zuo H, Tao J, Shi H, He J, Zhou Z, Zhang C. Platelet-mimicking nanoparticles co-loaded with W₁₈O₄₉ and metformin alleviate tumor hypoxia for enhanced photodynamic therapy and photothermal therapy. Acta Biomater. 2018;80:296–307.

[205] Jiang Q, Liu Y, Guo R, et al. Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors. Biomaterials. 2019;192:292–308.

[206] Peng J, Yang Q, Li W, et al. Erythrocyte-membrane-coated Prussian blue/manganese dioxide nanoparticles as H₂O₂-responsive oxygen generators to enhance cancer chemotherapy/photothermal therapy. ACS Appl Mater Interfaces. 2017;9(51):44410–44422.

[207] Guo Y, Wang D, Song Q, et al. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma. ACS Nano. 2015;9(7):6918–6933.

[208] Zheng D, Yu P, Wei Z, Zhong C, Wu M, Liu X. RBC membrane camouflaged semiconducting polymer nanoparticles for near-infrared photoacoustic imaging and photothermal therapy. Nano Micro Lett. 2020;12(1):94.

[209] Xie X, Wang H, Williams GR, et al. Erythrocyte membrane cloaked curcumin-loaded nanoparticles for enhanced chemotherapy. Pharmaceutics. 2019;11(9):429.

[210] Daniyal M, Jian Y, Xiao F, et al. Development of a nanodrug-delivery system camouflaged by erythrocyte membranes for the chemo/phototherapy of cancer. Nanomedicine. 2020;15(7):691–709.

[211] Li C, Yang XQ, An J, et al. Red blood cell membrane-enveloped O₂ self-supplementing biomimetic nanoparticles for tumor imaging-guided enhanced sonodynamic therapy. Theranostics. 2020;10(2):867–879.

[212] Wang P, Jiang F, Chen B, et al. Bioinspired red blood cell membrane-encapsulated biomimetic nanoconstructs for synergistic and efficacious chemo-photothermal therapy. Colloids Surf B. 2020;189:110842.

[213] Li M, Fang H, Liu Q, et al. Red blood cell membrane-coated upconversion nanoparticles for pretargeted multimodality imaging of triple-negative breast cancer. Biomater Sci. 2020;8(7):1802–1814.

[214] Wang S, Yin Y, Song W, et al. Red-blood-cell-membrane-enveloped magnetic nanoclusters as a biomimetic theranostic nanoplatform for bimodal imaging-guided cancer photothermal therapy. J Mater Chem B. 2020;8(4):803–812.

[215] Lin Y, Zhong Y, Chen Y, et al. Ligand-modified erythrocyte membrane-cloaked metal-organic framework nanoparticles for targeted antitumor therapy. Mol Pharmaceutics. 2020;17(9):3328–3341.

[216] Zhao Y, Wang J, Cai X, Ding P, Lv H, Pei R. Metal-organic frameworks with enhanced photodynamic therapy: synthesis, erythrocyte membrane camouflage, and aptamer-targeted aggregation. ACS Appl Mater Interfaces. 2020;12(21):23697–23706.

[217] Nguyen TDT, Marasini R, Rayamajhi S, Aparicio C, Biller D, Aryal S. Erythrocyte membrane concealed paramagnetic polymeric nanoparticle for contrast-enhanced magnetic resonance imaging. Nanoscale. 2020;12(6):4137–4149.

[218] Long Y, Wu X, Li Z, Fan J, Hu X, Liu B. PEGylated WS₂ nanodrug system with erythrocyte membrane coating for chemo/photothermal therapy of cervical cancer. Biomater Sci. 2020;8(18):5088–5105.

[219] Lian Y, Wang X, Guo P, et al. Erythrocyte membrane-coated arsenic trioxide-loaded sodium alginate nanoparticles for tumor therapy. Pharmaceutics. 2019;12(1):21.

[220] Liu W, Ruan M, Wang Y, et al. Light-triggered biomimetic nanoerythrocyte for tumor-targeted lung metastatic combination therapy of malignant melanoma. Small. 2018;14(38):e1801754.

[221] Ding K, Zheng C, Sun L, Liu X, Yin Y, Wang L. NIR light-induced tumor phototherapy using ICG delivery system based on platelet-membrane-camouflaged hollow bismuth selenide nanoparticles. Chin Chem Lett. 2020;31(5):1168–1172.

[222] Chen Y, Zhao G, Wang S, et al. Platelet-membrane-camouflaged bismuth sulfide nanorods for synergistic radio-photothermal therapy against cancer. Biomater Sci. 2019;7(8):3450–3459.

[223] Wu L, Xie W, Zan HM, et al. Platelet membrane-coated nanoparticles for targeted drug delivery and local chemo-photothermal therapy of orthotopic hepatocellular carcinoma. J Mater Chem B. 2020;8(21):4648–4659.

[224] Mei D, Gong L, Zou Y, et al. Platelet membrane-cloaked paclitaxel-nanocrystals augment postoperative chemotherapeutical efficacy. J Controll Release. 2020;324:341–353.

[225] Xuan M, Shao J, Dai L, Li J, He Q. Macrophage cell membrane camouflaged Au nanoshells for in vivo prolonged circulation life and enhanced cancer photothermal therapy. ACS Appl Mater Interfaces. 2016;8(15):9610–9618.

[226] Zhuang J, Gong H, Zhou J, et al. Targeted gene silencing in vivo by platelet membrane-coated metal-organic framework nanoparticles. Sci Adv. 2020;6(13):eaaz6108.

[227] Kim MW, Lee G, Niidome T, Komohara Y, Lee R, Park YI. Platelet-like gold nanostars for cancer therapy: the ability to treat cancer and evade immune reactions. Front Bioeng Biotechnol. 2020;8:133.

[228] Wang H, Bremner DH, Wu K, et al. Platelet membrane biomimetic bufalin-loaded hollow MnO₂ nanoparticles for MRI-guided chemo-chemodynamic combined therapy of cancer. Chem Eng J. 2020;382:122848.

[229] Chen H, Tian J, He W, Guo Z. H₂O₂-activatable and O₂-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells. J Am Chem Soc. 2015;137(4):1539–1547.

[230] Zhu W, Dong Z, Fu T, et al. Modulation of hypoxia in solid tumor microenvironment with MnO₂ nanoparticles to enhance photodynamic therapy. Adv Funct Mater. 2016;26(30):5490–5498.

[231] Li X, Kwon N, Guo T, Liu Z, Yoon J. Innovative strategies for hypoxic-tumor photodynamic therapy. Angew Chem Int Ed. 2018;57(36):11522–11531.

[232] Chen J, Fan T, Xie Z, et al. Advances in nanomaterials for photodynamic therapy applications: status and challenges. Biomaterials. 2020;237:119827.

[233] Hu J-J, Lei Q, Zhang X-Z. Recent advances in photonanomedicines for enhanced cancer photodynamic therapy. Prog Mater Sci. 2020;114:100685.

[234] Gao C, Lin Z, Wang D, Wu Z, Xie H, He Q. Red blood cell-mimicking micromotor for active photodynamic cancer therapy. ACS Appl Mater Interfaces. 2019;11(26):23392–23400.

[235] Calixto G, Bernegossi J, de Freitas L, Fontana C, Chorilli M. Nanotechnology-based drug delivery systems for photodynamic therapy of cancer: a review. Molecules. 2016;21(3):342.

[236] Pandey RK, Kessel D, Dougherty TJ. Handbook of photodynamic therapy: updates on recent applications of porphyrin-based compounds. World Scientific.2016.

[237] McNicholas K, MacGregor MN, Gleadle JM. In order for the light to shine so brightly, the darkness must be present—why do cancers fluoresce with 5-aminolaevulinic acid? Br J Cancer. 2019;121(8):631–639.

[238] Hu J, Tang Y, Elmenoufy AH, Xu H, Cheng Z, Yang X. Nanocomposite-based photodynamic therapy strategies for deep tumor treatment. Small. 2015;11(44):5860–5887.

[239] Jansen MHE, Mosterd K, Arits AHMM, et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. J Invest Dermatol. 2018;138(3):527–533.

[240] Fan W, Huang P, Chen X. Overcoming the Achilles’heel of photodynamic therapy. Chem Soc Rev. 2016;45(23):6488–6519.

[241] Li SY, Cheng H, Xie BR, et al. Cancer cell membrane camouflaged cascade bioreactor for cancer targeted starvation and photodynamic therapy. ACS Nano. 2017;11(7):7006–7018.

[242] Vankayala R, Hwang KC. Near-infrared-light-activatable nanomaterial-mediated phototheranostic nanomedicines: an emerging paradigm for cancer treatment. Adv Mater. 2018;30(23):e1706320.

[243] Abrahamse H, Hamblin MR. New photosensitizers for photodynamic therapy. Biochem J. 2016;473(4):347–364.

[244] Liang L, Care A, Zhang R, et al. Facile assembly of functional upconversion nanoparticles for targeted cancer imaging and photodynamic therapy. ACS Appl Mater Interfaces. 2016;8(19):11945–11953.

[245] Zhang X, Ai F, Sun T, Wang F, Zhu G. Multimodal upconversion nanoplatform with a mitochondria-targeted property for improved photodynamic therapy of cancer cells. Inorg Chem. 2016;55(8):3872–3880.

[246] Gao C, Lin Z, Wu Z, Lin X, He Q. Stem-cell-membrane camouflaging on near-infrared photoactivated upconversion nanoarchitectures for in vivo remote-controlled photodynamic therapy. ACS Appl Mater Interfaces. 2016;8(50):34252–34260.

[247] Lyu Y, Zeng J, Jiang Y, et al. Enhancing both biodegradability and efficacy of semiconducting polymer nanoparticles for photoacoustic imaging and photothermal therapy. ACS Nano. 2018;12(2):1801–1810.

[248] Ding Y, Zhu Y, Wei S, Zhou J, Shen J. Cancer cell membrane as gate keeper of mesoporous silica nanoparticles and photothermal-triggered membrane fusion to release the encapsulated anticancer drug. J Mater Sci. 2019;54(19):12794–12805.

[249] Liu S, Pan X, Liu H. Two-dimensional nanomaterials for photothermal therapy. Angew Chem Int Ed. 2020;59(15):5890–5900.

[250] Yang W, Liang H, Ma S, Wang D, Huang J. Gold nanoparticle based photothermal therapy: development and application for effective cancer treatment. Sustainable Mater Technol. 2019;22:e00109.

[251] Starosolski Z, Bhavane R, Ghaghada KB, Vasudevan SA, Kaay A, Annapragada A. Indocyanine green fluorescence in second near-infrared (NIR-II) window. PLoS ONE. 2017;12(11):e0187563.

[252] Feng Q, Liu Y, Huang J, Chen K, Huang J, Xiao K. Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings. Sci Rep. 2018;8(1):2082.

[253] Odda AH, Xu Y, Lin J, et al. Plasmonic MoO_3−x nanoparticles incorporated in Prussian blue frameworks exhibit highly efficient dual photothermal/photodynamic therapy. J Mater Chem B. 2019;7(12):2032–2042.

[254] Wang L, Chen S, Pei W, Huang B, Niu C. Magnetically targeted erythrocyte membrane coated nanosystem for synergistic photothermal/chemotherapy of cancer. J Mater Chem B. 2020;8(18):4132–4142.

[255] Wang P, Kankala RK, Chen B, et al. Cancer cytomembrane-cloaked Prussian blue nanoparticles enhance the efficacy of mild-temperature photothermal therapy by disrupting mitochondrial functions of cancer cells. ACS Appl Mater Interfaces. 2021;13(31):37563–37577.

[256] Jia J, Liu G, Xu W, et al. Fine-tuning the homometallic interface of Au-on-Au nanorods and their photothermal therapy in the NIR-II window. Angew Chem Int Ed. 2020;59(34):14443–14448.

[257] Ha M, Nam SH, Sim K, et al. Highly efficient photothermal therapy with cell-penetrating peptide-modified bumpy au triangular nanoprisms using low laser power and low probe dose. Nano Lett. 2021;21(1):731–739.

[258] Hu JJ, Cheng YJ, Zhang XZ. Recent advances in nanomaterials for enhanced photothermal therapy of tumors. Nanoscale. 2018;10(48):22657–22672.

[259] Liu T, Shi S, Liang C, et al. Iron oxide decorated MoS₂ nanosheets with double PEGylation for chelator-free radiolabeling and multimodal imaging guided photothermal therapy. ACS Nano. 2015;9(1):950–960.

[260] Viitala L, Pajari S, Lajunen T, et al. Photothermally triggered lipid bilayer phase transition and drug release from gold nanorod and indocyanine green encapsulated liposomes. Langmuir. 2016;32(18):4554–4563.

[261] Liu B, Li C, Chen G, et al. Synthesis and optimization of MoS₂@Fe₃O₄-ICG/Pt(IV) nanoflowers for MR/IR/PA bioimaging and combined PTT/PDT/chemotherapy triggered by 808 nm laser. Adv Sci. 2017;4(8):1600540.

[262] Xu PY, Zheng X, Kankala RK, Wang SB, Chen AZ. Advances in indocyanine green-based codelivery nanoplatforms for combinatorial therapy. ACS Biomater Sci Eng. 2021;7(3):939–962.

[263] Lee S, George Thomas R, Ju Moon M, et al. Near-infrared heptamethine cyanine based iron oxide nanoparticles for tumor targeted multimodal imaging and photothermal therapy. Sci Rep. 2017;7(1):2108.

[264] Fathy MM. Multifunctional thymoquinone-capped iron oxide nanoparticles for combined chemo-photothermal therapy of cancer. J Supercond Novel Magn. 2020;33(5):2125–2131.

[265] Espinosa A, Di Corato R, Kolosnjaj-Tabi J, Flaud P, Pellegrino T, Wilhelm C. Duality of iron oxide nanoparticles in cancer therapy: amplification of heating efficiency by magnetic hyperthermia and photothermal bimodal treatment. ACS Nano. 2016;10(2):2436–2446.

[266] Bu L-L, Rao L, Yu G-T, et al. Cancer stem cell-platelet hybrid membrane-coated magnetic nanoparticles for enhanced photothermal therapy of head and neck squamous cell carcinoma. Adv Funct Mater. 2019;29(10):1807733.

[267] Chen H, Ma Y, Wang X, Wu X, Zha Z. Facile Synthesis of Prussian Blue Nanoparticles as pH-Responsive Drug Carriers for Combined Photothermal-chemo Treatment of Cancer. Vol 7. RSC Publishing;2017:248–255.

[268] Xue P, Bao J, Zhang L, et al. Functional magnetic Prussian blue nanoparticles for enhanced gene transfection and photothermal ablation of tumor cells. J Mater Chem B. 2016;4(27):4717–4725.

[269] Cai X, Gao W, Ma M, et al. A Prussian blue-based core–shell hollow-structured mesoporous nanoparticle as a smart theranostic agent with ultrahigh pH-responsive longitudinal relaxivity. Adv Mater. 2015;27(41):6382–6389.

[270] Liao J, Li W, Peng J, et al. Combined cancer photothermal–chemotherapy based on doxorubicin/gold nanorod-loaded polymersomes. Theranostics. 2015;5(4):345–356.

[271] Li W, Peng J, Tan L, et al. Mild photothermal therapy/photodynamic therapy/chemotherapy of breast cancer by Lyp-1 modified Docetaxel/IR820 Co-loaded micelles. Biomaterials. 2016;106:119–133.

[272] Movia D, Benhaddada M, Spadavecchia J, Prina-Mello A. Latest advances in combining gold nanomaterials with physical stimuli towards new responsive therapeutic and diagnostic strategies. Precis Nanomed. 2020;3(2):495–524.

[273] Rüegg C, Reis C, Rafiee S, et al. A bio-inspired amplification cascade for the detection of rare cancer cells. Chimia. 2019;73(1):63–68.

[274] Maruf M, George A, Canfield S, et al. PD17-11 Phase II clinical trial: short-term oncologic outcomes of nanoparticle-directed focal photothermal laser ablation. J Urol. 2020;203(Suppl 4): e373–e374.

[275] Chafe SC, Vizeacoumar FS, Venkateswaran G, et al. Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. Sci Adv. 2021;7(35):eabj0364.

[276] Belisario DC, Kopecka J, Pasino M, et al. Hypoxia dictates metabolic rewiring of tumors: implications for chemoresistance. Cells. 2020;9(12):2598.

[277] Patel A, Sant S. Hypoxic tumor microenvironment: opportunities to develop targeted therapies. Biotech Adv. 2016;34(5):803–812.

[278] Bernabeu MO, Köry J, Grogan JA, et al. Abnormal morphology biases hematocrit distribution in tumor vasculature and contributes to heterogeneity in tissue oxygenation. Proc Natl Acad Sci. 2020;117(45):27811–27819.

[279] Siemann DW, Horsman MR. Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacol Ther. 2015;153:107–124.

[280] Sørensen BS, Horsman MR. Tumor hypoxia: impact on radiation therapy and molecular pathways. Front Oncol. 2020;10:562.

[281] Jeong SK, Kim JS, Lee CG, et al. Tumor associated macrophages provide the survival resistance of tumor cells to hypoxic microenvironmental condition through IL-6 receptor-mediated signals. Immunobiology. 2017;222(1):55–65.

[282] Zhang H, Xu H, Ashby, Jr. CR, Assaraf YG, Chen ZS, Liu HM. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). Med Res Rev. 2021;41(1):525–555.

[283] Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352(6282):175–180.

[284] Ahmad J, Akhter S, Ahmed Khan M, et al. Engineered nanoparticles against MDR in cancer: the state of the art and its prospective. Curr Pharm Des. 2016;22(28):4360–4373.

[285] Yu P, Han X, Yin L, et al. Artificial red blood cells constructed by replacing heme with perfluorodecalin for hypoxia-induced radioresistance. Adv Ther. 2019;2(6):1900031.

[286] Sun X, Ni N, Ma Y, Wang Y, Leong DT. Retooling cancer nanotherapeutics’ entry into tumors to alleviate tumoral hypoxia. Small. 2020;16(41):e2003000.

[287] Drakesmith H, Nemeth E, Ganz T. Ironing out ferroportin. Cell Metab. 2015;22(5):777–787.

[288] Tai YH, Wu HL, Mandell MS, Tsou MY, Chang KY. The association of allogeneic blood transfusion and the recurrence of hepatic cancer after surgical resection. Anaesthesia. 2020;75(4):464–471.

[289] Jansman MMT, Liu X, Kempen P, et al. Hemoglobin-based oxygen carriers incorporating nanozymes for the depletion of reactive oxygen species. ACS Appl Mater Interfaces. 2020;12(45):50275–50286.

[290] Jia Y, Duan L, Li J. Hemoglobin-based nanoarchitectonic assemblies as oxygen carriers. Adv Mater. 2016;28(6):1312–1318.

[291] Jansman MMT, Hosta-Rigau L. Recent and prominent examples of nano-and microarchitectures as hemoglobin-based oxygen carriers. Adv Colloid Interface Sci. 2018;260:65–84.

[292] Wang Q, Zhang R, Lu M, et al. Bioinspired polydopamine-coated hemoglobin as potential oxygen carrier with antioxidant properties. Biomacromolecules. 2017;18(4):1333–1341.

[293] Taguchi K, Yamasaki K, Maruyama T, Otagiri M. Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers. J Funct Biomater. 2017;8(1):11.

[294] Sen Gupta A. Bio-inspired nanomedicine strategies for artificial blood components. WIREs Nanomed Nanobiotechnol. 2017;9(6):1464.

[295] Rikihisa N, Watanabe S, Saito Y, Sakai H. Artificial red blood cells as potential photosensitizers in dye laser treatment against port-wine stains. J Funct Biomater. 2017;8(2):14.

[296] Taguchi K, Yamasaki K, Sakai H, Maruyama T, Otagiri M. The use of hemoglobin vesicles for delivering medicinal gas for the treatment of intractable disorders. J Pharm Sci. 2017;106(9):2392–2400.

[297] Yang J, Li W, Luo L, et al. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance. Biomaterials. 2018;182:145–156.

[298] Kawaguchi F, Kawaguchi AT, Murayama C, Kamijo A, Haida M. Liposome-encapsulated hemoglobin improves tumor oxygenation as detected by near-infrared spectroscopy in colon carcinoma in mice. Artif Organs. 2017;41(4):327–335.

[299] Azuma H, Fujihara M, Sakai H. Biocompatibility of HbV: liposome-encapsulated hemoglobin molecules—liposome effects on immune function. J Funct Biomater. 2017;8(3):24.

[300] Sen Gupta A. Role of particle size, shape, and stiffness in design of intravascular drug delivery systems: insights from computations, experiments, and nature. WIREs Nanomed Nanobiotechnol. 2016;8(2):255–270.

[301] Xiong Y, Liu ZZ, Georgieva R, et al. Nonvasoconstrictive hemoglobin particles as oxygen carriers. ACS Nano. 2013;7(9):7454–7461.

[302] Kao I, Xiong Y, Steffen A, et al. Preclinical in vitro safety investigations of submicron sized hemoglobin based oxygen carrier HbMP-700. Artif Organs. 2018;42(5):549–559.

[303] Richardson JJ, Björnmalm M, Caruso F. Technology-driven layer-by-layer assembly of nanofilms. Science. 2015;348(6233):aaa2491.

[304] Ighodaro OM, Akinloye OA. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): their fundamental role in the entire antioxidant defence grid. Alexandria J Med. 2017;54(4):287–293.

[305] Duhamel J, Karayianni M, Limpouchová Z, et al. Fluorescence studies of polymer containing systems. Springer. 2016;16.

[306] Hu J, Wang Q, Wang Y, et al. Polydopamine-based surface modification of hemoglobin particles for stability enhancement of oxygen carriers. J Colloid Interface Sci. 2020;571:326–336.

[307] Liu WL, Liu T, Zou MZ, et al. Aggressive man-made red blood cells for hypoxia-resistant photodynamic therapy. Adv Mater. 2018;30(35):e1802006.

[308] Bi H, Dai Y, Yang P, et al. Glutathione and H₂O₂ consumption promoted photodynamic and chemotherapy based on biodegradable MnO₂-Pt@Au₂₅ nanosheets. Chem Eng J. 2019;356:543–553.

[309] Chen H, Fu Y, Feng K, et al. Polydopamine-coated UiO-66 nanoparticles loaded with perfluorotributylamine/tirapazamine for hypoxia-activated osteosarcoma therapy. J Nanobiotechnology. 2021;19(1):298.

[310] Lam JKW, Chow MYT, Zhang Y, Leung SWS. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther—Nucleic Acids. 2015;4(9):e252.

[311] Wang BK, Yu XF, Wang JH, et al. Gold-nanorods-siRNA nanoplex for improved photothermal therapy by gene silencing. Biomaterials. 2016;78:27–39.

[312] Kim HJ, Kim A, Miyata K, Kataoka K. Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv Drug Deliv Rev. 2016;104:61–77.

[313] Mirzaei H, Yazdi F, Salehi R, Mirzaei H. SiRNA and epigenetic aberrations in ovarian cancer. J Cancer Res Ther. 2016;12(2):498–508.

[314] Kang SH, Revuri V, Lee SJ, et al. Oral siRNA delivery to treat colorectal liver metastases. ACS Nano. 2017;11(10):10417–10429.

[315] Xu X, Wu J, Liu Y, et al. Multifunctional envelope-type siRNA delivery nanoparticle platform for prostate cancer therapy. ACS Nano. 2017;11(3):2618–2627.

[316] Liu HM, Zhang YF, Xie YD, et al. Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy. Int J Nanomed. 2017;12:1065–1083.

[317] Young SWS, Stenzel M, Jia-Lin Y. Nanoparticle-siRNA: a potential cancer therapy? Crit Rev Oncol Hematol. 2016;98:159–169.

[318] Mirkin CA, Meade TJ, Petrosko SH, Stegh AH. Nanotechnology-based precision tools for the detection and treatment of cancer. In: Cancer Treatment and Research. Exploring the Tumor Microenvironment with Nanoparticles. Vol 166, 2015:193–226 (Chapter 9).

[319] Pelletier JF, Sun L, Wise KS, et al. Genetic requirements for cell division in a genomically minimal cell. Cell. 2021;184(9):2430–2440.e16, e2416.

[320] Hutchison, 3rd CA, Chuang RY, Noskov VN, et al. Design and synthesis of a minimal bacterial genome. Science. 2016;351(6280):aad6253.

[321] Zubaite G, Hindley JW, Ces O, Elani Y. Dynamic reconfiguration of subcompartment architectures in artificial cells. ACS Nano. 2022;16(6):9389–9400.

[322] Bhattacharya A, Niederholtmeyer H, Podolsky KA, et al. Lipid sponge droplets as programmable synthetic organelles. Proc Natl Acad Sci. 2020;117(31):18206–18215.

[323] Cho CJ, Niederholtmeyer H, Seo H, Bhattacharya A, Devaraj NK. Functionalizing lipid sponge droplets with DNA. ChemSystemsChem. 2022;4(3):e202100045.

[324] Niederholtmeyer H, Chaggan C, Devaraj NK. Communication and quorum sensing in non-living mimics of eukaryotic cells. Nat Commun. 2018;9(1):5027.

[325] Denis H, Razia C, Jefferson S, Michael B. Blue Light-activatable DNA for Remote Control of Cell-free Logic Gates and Synthetic Cells. ChemRxiv. Vol 2, 2022.

[326] Zhan P, Jahnke K, Liu N, Göpfrich K. Functional DNA-based cytoskeletons for synthetic cells. Nat Chem. 2022;14(8):958–963.

[327] Ehrlich H, Luczak M, Ziganshin R, et al. Arrested in glass: actin within sophisticated architectures of biosilica in sponges. Adv Sci. 2022;9(11):e2105059.

[328] Wagner AM, Eto H, Joseph A, et al. Dendrimersome synthetic cells harbor cell division machinery of bacteria. Adv Mater. 2022;34(28):e2202364.

[329] Karoui H, Patwal PS, Pavan Kumar BVVS, Martin, N. Chemical communication in artificial cells: basic concepts, design and challenges. Front Mol Biosci. 2022;9:880525.

[330] Shin J, Cole BD, Shan T, Jang Y. Heterogeneous synthetic vesicles toward artificial cells: engineering structure and composition of membranes for multimodal functionalities. Biomacromolecules. 2022;23(4):1505–1518.

[331] Yang Q, Guo Z, Liu H, et al. A cascade signaling network between artificial cells switching activity of synthetic transmembrane channels. J Am Chem Soc. 2021;143(1):232–240.

[332] Dey S, Dorey A, Abraham L, et al. A reversibly gated protein-transporting membrane channel made of DNA. Nat Commun. 2022;13(1):2271.

[333] Mashima T, van Stevendaal MHME, Cornelissens FRA, et al. DNA-mediated protein shuttling between coacervate-based artificial cells. Angew Chem Int Ed. 2022;61(17):e202115041.

[334] Buddingh’ BC, Elzinga J, van Hest JCM. Intercellular communication between artificial cells by allosteric amplification of a molecular signal. Nat Commun. 2020;11(1):1652.

[335] Lentini R, Martín NY, Forlin M, et al. Two-way chemical communication between artificial and natural cells. ACS Cent Sci. 2017;3(2):117–123.

[336] Aufinger L, Simmel FC. Establishing communication between artificial cells. Chem Eur J. 2019;25(55):12659–12670.

[337] Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145–161.

[338] Ahmad A, Uddin S, Steinhoff M. CAR-T cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-cell lymphomas. Int J Mol Sci. 2020;21(11):3906.

[339] Leon-Triana O, Sabir S, Calvo GF, et al. CAR T cell therapy in B-cell acute lymphoblastic leukaemia: insights from mathematical models. Commun Nonlinear Sci Numer Simul. 2021;94:105570.

[340] Myers RM, Li Y, Barz Leahy A, et al. Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol. 2021;39(27):3044–3055.

[341] D’Ovidio TJ, Ciccolini K, Kalac M, Osman K, Steinberg A. CD19-targeted CAR T cell therapy for concomitant diffuse large B cell lymphoma and myeloma. Blood. 2021;138(Suppl 1):4811.

[342] Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.

[343] Castellarin M, Sands C, Da T, et al. A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. JCI Insight. 2020;5(14):e136012.

[344] Yip A, Webster RM. The market for chimeric antigen receptor T cell therapies. Nat Rev Drug Discovery. 2018;17(3):161–162.

[345] Lanitis E, Coukos G, Irving M. All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy. Curr Opin Biotechnol. 2020;65:75–87.

[346] Zhang C, Zhuang Q, Liu J, Liu X. Synthetic biology in chimeric antigen receptor T (CAR T) cell engineering. ACS Synth Biol. 2022;11(1):1–15.

[347] Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372–385.

[348] Zhang M, Cheng S, Jin Y, Zhang N, Wang Y. Membrane engineering of cell membrane biomimetic nanoparticles for nanoscale therapeutics. Clin Transl Med. 2021;11(2):e292.

[349] Ma W, Zhu D, Li J, et al. Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment. Theranostics. 2020;10(3):1281–1295.

[350] Le TMD, Yoon AR, Thambi T, Yun CO. Polymeric systems for cancer immunotherapy: a review. Front Immunol. 2022;13:826876.

[351] Nawaz W, Xu S, Li Y, Huang B, Wu X, Wu Z. Nanotechnology and immunoengineering: how nanotechnology can boost CAR-T therapy. Acta Biomater. 2020;109:21–36.

[352] Chung HK, Zou X, Bajar BT, et al. A compact synthetic pathway rewires cancer signaling to therapeutic effector release. Science. 2019;364(6439):eaat6982.

[353] Ehrlich H, Bailey E, Wysokowski M, Jesionowski T. Forced biomineralization: a review. Biomimetics. 2021;6(3):46.

[354] Kim K, Chen CL, Truong Q, Shen AM, Chen Y. A carbon nanotube synapse with dynamic logic and learning. Adv Mater. 2013;25(12):1693–1698.

[355] Herrera VL, Colby AH, Ruiz-Opazo N, Coleman DG, Grinstaff MW. Nucleic acid nanomedicines in Phase II/III clinical trials: translation of nucleic acid therapies for reprogramming cells. Nanomedicine. 2018;13(16):2083–2098.

[356] Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25–38.

[357] Hua S, de Matos MBC, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol. 2018;9:790.

[358] Chung YH, Cai H, Steinmetz NF. Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications. Adv Drug Deliv Rev. 2020;156:214–235.https://doi.org/10.1016/j.addr.2020.06.024

RIGHTS & PERMISSIONS

2024 The Authors. Interdisciplinary Materials published by Wuhan University of Technology and John Wiley & Sons Australia, Ltd.